Positive phase III data on Gilead Science?s (GILD) integrase inhibitor, elvitegravir, is encouraging news for the company?s most important pipeline product ? the four-drugs-in-one-tablet HIV therapy dubbed Quad.
Elvitegravir is a vital component of Quad; it is not expected to be hugely important on its own but evidence of safety and effectiveness ticks an important box (Event - Gilead looks for win in integrase inhibitor class, December 6, 2010). A longer term read out from the study has been requested by the FDA, which will not come for another 48 weeks, but investors were comfortable enough for now to send Gilead shares 3% higher in early trade, to $41.62.
Non-inferior
The California drug developer said the study, called 145, met its primary endpoint ? non-inferiority at week 48 compared to Merck & Co?s (MRK) blockbuster integrase inhibitor, Isentress. The main difference between the two is dosing ? elvitegravir is once
Complete Story »
Sanaa Lathan Ana Beatriz Barros Maria Menounos Shakira Leslie Bibb
No comments:
Post a Comment